Evogene (NASDAQ:EVGN) Issues Earnings Results

Evogene (NASDAQ:EVGN) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.14, Zacks reports. Evogene had a negative return on equity of 158.82% and a negative net margin of 638.12%.

Evogene Trading Down 6.8%

Shares of EVGN stock opened at $0.56 on Tuesday. The stock has a market cap of $4.88 million, a P/E ratio of -0.40 and a beta of 1.40. Evogene has a 1 year low of $0.37 and a 1 year high of $1.50. The stock has a 50 day simple moving average of $0.53 and a 200 day simple moving average of $0.72.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a report on Wednesday, July 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Insider Buying and Selling

In related news, Director Leon Recanati acquired 460,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was purchased at an average cost of $0.64 per share, with a total value of $294,400.00. Following the acquisition, the director directly owned 1,343,886 shares of the company’s stock, valued at approximately $860,087.04. The trade was a 52.04% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.40% of the stock is currently owned by company insiders.

Institutional Trading of Evogene

Hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in shares of Evogene in the fourth quarter worth $25,000. Jane Street Group LLC grew its stake in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,387 shares during the period. Finally, Citadel Advisors LLC grew its position in shares of Evogene by 169.4% during the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after buying an additional 36,206 shares during the period. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.